Dimethyl Sulfoxide
Sigma Aldrich Fine Chemicals Biosciences Dimethyl sulfoxide puriss.
Dimethyl sulfoxide (DMSO) is a polar solvent. DMSO activated by electrophile (oxalyl chloride) has been used to oxidize various alcohols (primary secondary allylic benzylic hindered and bicyclic). Carbonyl compounds are formed as reaction products. It has been proposed as an alternate solvent for methyl cellosolve for use in ninhydrin reaction due to its high stability.
Apexbio Technology LLC SBI-0206965 1884220-36-3 10mM (in 1mL DMSO)
SBI-0206965 (CAS 1884220-36-3) is a small-molecule inhibitor targeting ULK1 (UNC-51-like kinase 1) a serine/threonine kinase pivotal in regulating autophagy initiation ULK1 functions downstream of mTORC1 and is modulated by AMPK influencing cellular responses to nutrient deprivation In cellular assays using A549 cells SBI-0206965 at 5 mM effectively suppresses AZD8055-induced autophagy and increases apoptotic response upon nutrient starvation in MEFs U87MG glioblastoma and mouse lung cancer cell lines SBI-0206965 serves as a useful research tool for investigating autophagy pathways tumor cell survival and apoptosis mechanisms
Apexbio Technology LLC Mirabegron (YM178) 223673-61-8 10mM (in 1mL DMSO)
Mirabegron (YM178 CAS 223673-61-8) is a selective agonist targeting the -adrenergic receptor ( -AR) Activation of -AR influences physiological responses in tissues including adipose cells prostate gastrointestinal tract and primarily the urinary bladder In CHO cells expressing human -adrenergic receptor subtypes mirabegron demonstrated selective agonist properties at -AR (EC 22 4 nM) showing minimal activity at - and -AR subtypes Animal studies revealed mirabegron reduced rhythmic bladder contraction frequency without affecting amplitude Its selective -AR agonist profile makes mirabegron pertinent for research on bladder dysfunction particularly overactive bladder conditions
Apexbio Technology LLC Eltrombopag 496775-61-2 10mM (in 1mL DMSO)
Eltrombopag is a small molecule orally bioavailable non-peptide agonist targeting the thrombopoietin (TPO) receptor also known as c-Mpl receptor Upon activating this receptor pathway eltrombopag promotes intracellular signaling leading to increased proliferation and differentiation of megakaryocyte progenitor cells thereby stimulating platelet production (thrombopoiesis) In biochemical assays eltrombopag shows potent activity exhibiting an IC50 value of approximately 0 69 M As a research tool this compound is utilized widely in studies investigating mechanisms regulating platelet homeostasis thrombocytopenia-related diseases and efforts to elucidate novel therapeutic strategies targeting hematopoietic lineage differentiation
Apexbio Technology LLC XL-888 1149705-71-4 10mM (in 1mL DMSO)
XL-888 (CAS 1149705-71-4) is an orally bioavailable small molecule inhibitor targeting heat shock protein 90 (HSP90) It selectively inhibits HSP90 and HSP90 with IC50 values of 22 nM and 44 nM respectively while exhibiting markedly weaker inhibition against a panel of other kinases Structural analyses indicated XL-888 binds HSP90 via hydrogen bonding interactions involving the Asp93 residue In tumor cell assays XL-888 potently suppresses proliferation with IC50 values in the range of 0 1-45 5 nM XL-888 is used in oncology research particularly for studying resistance mechanisms to targeted therapies
Apexbio Technology LLC Dofetilide 115256-11-6 10mM (in 1mL DMSO)
Dofetilide (CAS 115256-11-6) chemically designated as UK 68789 is a class III antiarrhythmic small molecule that selectively inhibits the rapid delayed rectifier potassium channel (IKr) This inhibition leads to prolonged ventricular action potential duration and extended effective refractory periods in cardiac cells Noted for favorable oral bioavailability Dofetilide is extensively utilized in cardiac electrophysiological research including studies aimed at elucidating arrhythmogenic mechanisms linked to IKr channel function assessing novel antiarrhythmic candidates and exploring physiological and pathological aspects of cardiac rhythm regulation
Apexbio Technology LLC WZ4003 1214265-58-3 10mM (in 1mL DMSO)
WZ4003 (CAS 1214265-58-3) is a selective inhibitor targeting NUAK1 and NUAK2 kinases members of the AMP-activated protein kinase (AMPK) family activated by tumor suppressor kinase LKB1 WZ4003 inhibits NUAK1 and NUAK2 with IC50 values of 20 nM and 100 nM respectively In cellular assays treatment with WZ4003 reduces NUAK1-mediated phosphorylation of MYPT1 at Ser445 It suppresses cell proliferation migration of mouse embryonic fibroblasts and invasion of U2OS cells Thus WZ4003 serves as a valuable tool for investigating NUAK kinase functions in cell proliferation mobility and signaling mechanisms relevant to oncology research
Apexbio Technology LLC GSK2334470 1227911-45-6 10mM (in 1mL DMSO)
GSK2334470 (CAS 1227911-45-6) is a highly selective inhibitor of 3-phosphoinositide-dependent protein kinase-1 (PDK1) demonstrating an IC50 of approximately 10 nM It specifically blocks PDK1-mediated phosphorylation of substrate proteins including Akt1 S6K1 and SGK isoforms inhibiting their T-loop phosphorylation sites GSK2334470 does not significantly inhibit other tested protein or lipid kinases This compound facilitates mechanistic research into signaling pathways regulated by PDK1 particularly those involving Akt and downstream effectors in cellular contexts
Apexbio Technology LLC C646 328968-36-1 10mM (in 1mL DMSO)
C646 (CAS 328968-36-1) is a small molecule pyrazolone derivative that functions as a selective competitive inhibitor of the histone acetyltransferase (HAT) activity of p300 It binds to the active site of p300 forming hydrogen bonds with residues Thr1411 Tyr1467 Trp1466 and Arg1410 C646 demonstrates a Ki of 400 nM and an IC50 of 1 6 M against p300 and also inhibits several p300 point mutants By specifically targeting p300-mediated protein acetylation C646 serves as a valuable research tool in studies investigating histone modification and gene transcription regulation
Apexbio Technology LLC Azaguanine-8 134-58-7 10mM (in 1mL DMSO)
Azaguanine-8 (CAS 134-58-7) is a synthetic purine analog utilized in biomedical research due to its antineoplastic properties Structurally similar to guanine Azaguanine-8 exerts its biological activity by competitively interfering with guanine metabolism subsequently disrupting nucleic acid synthesis and cellular replication pathways Through this mechanism the compound demonstrates inhibitory effects on cell proliferation making it a valuable tool in investigating nucleic acid metabolism and cancer biology in preclinical studies
Apexbio Technology LLC BYL-719 1217486-61-7 10mM (in 1mL DMSO)
BYL-719 (CAS 1217486-61-7) is a selective inhibitor of PI3K demonstrating minimal activity against PI3K or isoforms Through targeting PI3K an essential node frequently dysregulated via PIK3CA mutations in various cancers BYL-719 effectively disrupts downstream proliferative signaling In biochemical assays BYL-719 shows potent inhibition of PI3K with an IC50 of 5 nM Preclinical evaluations indicate dose-dependent antitumor efficacy in xenograft tumor models and proliferation arrest and apoptosis induction in multiple myeloma cell lines exhibiting PIK3CA overexpression Clinically initial studies reveal manageable safety profiles and preliminary antitumor responses notably in PIK3CA-mutant malignancies supporting continued exploration in oncology research settings
Apexbio Technology LLC Atglistatin 1469924-27-3 10mM (in 1mL DMSO)
Atglistatin (CAS 1469924-27-3) is a small-molecule inhibitor selective for adipose triglyceride lipase (ATGL) an enzyme that catalyzes the rate-limiting step in triglyceride hydrolysis releasing fatty acids from cellular triglyceride stores Atglistatin inhibits ATGL activity competitively with an IC50 of 0 7 M and Ki of 355 nM In mouse white adipose tissue lysates atglistatin decreased triglyceride hydrolase activity by approximately 78% effectively reducing fatty acid and glycerol release This compound serves as a valuable tool in lipid metabolism and metabolic disease research
Apexbio Technology LLC Calcifediol 19356-17-3 10mM (in 1mL DMSO)
Calcifediol also termed calcidiol is a hydroxylated vitamin D3 metabolite and the primary circulating form of vitamin D3 in humans Functioning as a prehormone it undergoes further hydroxylation to calcitriol which activates vitamin D receptor (VDR) signaling pathways In vitro assays indicate that calcifediol induces CYP24A1 expression (EC50 70 nM) and thrombomodulin expression at concentrations between 10-100 nM Calcifediol dose-dependently promotes nuclear translocation of VDR at concentrations from 0 1 to 10 M in cultured cells In vivo experiments demonstrated that calcifediol administration influences calcium binding protein expression and calcium transport Clinically calcifediol administration rapidly elevates circulating 25(OH)D3 concentrations facilitating precise modulation of vitamin D status Therefore calcifediol is utilized in biomedical research related to vitamin D metabolism calcium homeostasis and VDR-associated pathways
Apexbio Technology LLC Cyclopamine 4449-51-8 10mM (in 1mL DMSO)
Cyclopamine (CAS 4449-51-8) is a naturally occurring steroidal alkaloid that selectively inhibits the Hedgehog (Hh) signaling pathway a conserved cascade involved in cellular proliferation and differentiation In human breast cancer cell lines (MCF-7 and MDA-MB-231) cyclopamine treatment (10 20 M) significantly suppresses proliferation induces cell cycle arrest at G1 phase and reduces invasive capabilities In FXR-bla assays cyclopamine exhibits an EC50 of 10 57 M As an Hh-antagonist it is widely utilized in research examining embryogenesis cancer biology tumor invasiveness and developmental defects
Apexbio Technology LLC GZD824 1421783-64-3 10mM (in 1mL DMSO)
GZD824 (CAS 1421783-64-3) is an orally bioavailable inhibitor of the Bcr-Abl kinase a fusion protein exhibiting tyrosine kinase activity involved in regulating cell cycle progression and genomic stability GZD824 binds competitively to the ATP-binding site of Abl kinase effectively inhibiting the phosphorylation and activation of both wild-type (WT) and resistant mutant forms (e g T315I E255K G250E Q252H H396P M351T and Y253F) GZD824 demonstrates sub-nanomolar IC50 values and substantially reduces proliferation in Bcr-Abl-expressing Ba/F3 cell models Preclinical studies in mouse xenograft leukemia models show GZD824 suppresses tumor growth highlighting its potential applicability in research into resistance mechanisms and targeted leukemia therapies